Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S. Harrison C, et al. Among authors: ross d. Expert Rev Hematol. 2013 Oct;6(5):511-23. doi: 10.1586/17474086.2013.827413. Epub 2013 Oct 2. Expert Rev Hematol. 2013. PMID: 24083419 Free PMC article. Review.
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators. Verstovsek S, et al. Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23. Haematologica. 2015. PMID: 25616577 Free PMC article.
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. Vannucchi AM, et al. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069290 Free PMC article. Clinical Trial.
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK. Cervantes F, et al. Leukemia. 2021 Dec;35(12):3455-3465. doi: 10.1038/s41375-021-01261-x. Epub 2021 May 20. Leukemia. 2021. PMID: 34017073 Free PMC article. Clinical Trial.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins A, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Verstovsek S. Mesa RA, et al. Cancer Med. 2023 May;12(9):10612-10624. doi: 10.1002/cam4.5799. Epub 2023 Apr 6. Cancer Med. 2023. PMID: 37021939 Free PMC article. Clinical Trial.
Incidence of blast phase in myelofibrosis according to anemia severity.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian JJ, Elli EM, Polverelli N, Gotlib J, Albano F, Silver RT, Benevolo G, Ross DM, Devos T, Borsani O, Barbui T, Porta MGD, Bertù L, Komrokji R, Vannucchi AM, Passamonti F. Mora B, et al. EJHaem. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601878 Free PMC article.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Mesa RA, Harrison C, Palmer JM, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AC, Leahy MF, Kawashima J, Ro S, Donahue R, Gorsh B, Deheshi S, Verstovsek S. Mesa RA, et al. Hemasphere. 2023 Oct 24;7(11):e966. doi: 10.1097/HS9.0000000000000966. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37901848 Free PMC article.
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK. Cervantes F, et al. Leukemia. 2021 Dec;35(12):3626. doi: 10.1038/s41375-021-01396-x. Leukemia. 2021. PMID: 34475521 Free PMC article. No abstract available.
4,252 results